Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the
systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on
circulating vascular endothelial growth factor. In the present prospective study, the
investigators evaluated serum drug levels and plasma free vascular endothelial growth factor
(VEGF) levels in patients with neovascular age-related macular degeneration following
intravitreal injections of ranibizumab, bevacizumab and aflibercept.